These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 17005364)

  • 1. [Is there a place for activated protein C (Xigris) in the treatment of severe imported malaria in the adult?].
    Nau A; Peytel E; Petrognani R
    Ann Fr Anesth Reanim; 2006 Oct; 25(10):1085-6. PubMed ID: 17005364
    [No Abstract]   [Full Text] [Related]  

  • 2. Xigris: reducing mortality in adult patients with severe sepsis.
    Larson AM
    Urol Nurs; 2002 Jun; 22(3):200-1. PubMed ID: 12087796
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of drotrecogin alfa in severe falciparum malaria.
    Robak O; Bojic A; Locker GJ; Laczika K; Ramharter M; Staudinger T
    Anaesth Intensive Care; 2010 Jul; 38(4):751-4. PubMed ID: 20715743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Activated protein C in severe Plasmodium falciparum malaria].
    Soto-Blanco JM; Yuste-Osorio E; Olivencia-Peña L; Matarán-Robles E
    Med Clin (Barc); 2011 May; 136(14):648-9. PubMed ID: 21051059
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical experience with xigris].
    Wyncoll D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():46-7. PubMed ID: 15359944
    [No Abstract]   [Full Text] [Related]  

  • 6. [Xigris and corticoids: what are the perspectives for the patient with severe sepsis?].
    Annane D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():43-5. PubMed ID: 15359943
    [No Abstract]   [Full Text] [Related]  

  • 7. The use of activated protein C in severe Plasmodium falciparum malaria.
    Rankin LG; Austin DL
    Anaesth Intensive Care; 2007 Jun; 35(3):428-32. PubMed ID: 17591142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Xigris--activated protein C].
    Tønnesen EK
    Ugeskr Laeger; 2004 Mar; 166(11):1002-4. PubMed ID: 15049235
    [No Abstract]   [Full Text] [Related]  

  • 9. Activated protein C (Xigris): a drug in trouble.
    Vangerow B; Mignini MA
    Acta Anaesthesiol Scand; 2007 Feb; 51(2):261-2. PubMed ID: 17261152
    [No Abstract]   [Full Text] [Related]  

  • 10. Twenty-four hour infusion of human recombinant activated protein C (Xigris) early in severe acute pancreatitis: The XIG-AP 1 trial.
    Miranda CJ; Mason JM; Babu BI; Sheen AJ; Eddleston JM; Parker MJ; Pemberton P; Siriwardena AK
    Pancreatology; 2015; 15(6):635-41. PubMed ID: 26547592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
    Heslet L; Nielsen JD; Schierbeck J; Andersen JS
    Ugeskr Laeger; 2004 Mar; 166(11):997-1002. PubMed ID: 15049234
    [No Abstract]   [Full Text] [Related]  

  • 12. Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death.
    Levi M
    Crit Care Med; 2003 Mar; 31(3):984-5. PubMed ID: 12627023
    [No Abstract]   [Full Text] [Related]  

  • 13. The Sepsis Saga: Consensus to Xigris.
    Dries DJ
    Air Med J; 2016; 35(4):194-6. PubMed ID: 27393750
    [No Abstract]   [Full Text] [Related]  

  • 14. The last Xigris® survivor.
    Barie PS
    Surg Infect (Larchmt); 2011 Dec; 12(6):423-5. PubMed ID: 22185189
    [No Abstract]   [Full Text] [Related]  

  • 15. [Surgical patients with severe sepsis: first results of the PROWESS study. Demographic data].
    Montravers P; Blaise M
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():38-9. PubMed ID: 15359941
    [No Abstract]   [Full Text] [Related]  

  • 16. Activated protein C (Xigris) treatment in sepsis: a drug in trouble.
    Gårdlund B
    Acta Anaesthesiol Scand; 2006 Sep; 50(8):907-10. PubMed ID: 16923083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical approach to the identification of patients suffering from severe sepsis with several organ failures for the administration of drotrecogin alfa (activated): from the PROWESS study to clinical practice].
    Dhainaut JF; Payen DM; Bernardin G; Gérard JL; Martin C; Perrotin D; Regnier B
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():53-64. PubMed ID: 15359946
    [No Abstract]   [Full Text] [Related]  

  • 18. Xigris is withdrawn from the market. A 10 year odyssey.
    Suter PM
    Minerva Anestesiol; 2011 Dec; 77(12):1128-9. PubMed ID: 22134426
    [No Abstract]   [Full Text] [Related]  

  • 19. Sepsis update: management of severe sepsis and septic shock in the emergency department after the withdrawal of Xigris.
    Green RS; Djogovic D; Howes D
    CJEM; 2012 Sep; 14(5):265-9. PubMed ID: 22967692
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of severe sepsis and multiple organ failure with activated protein C].
    Strøm JJ
    Ugeskr Laeger; 2004 Mar; 166(11):995. PubMed ID: 15049233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.